logo-loader
viewAllergy Therapeutics PLC

Allergy Therapeutics confident on the coming year as it reports 8% boost to revenues

Allergy Therapeutics PLC's (LON:AGY) Manuel Llobet and Nick Wykeman talk Proactive London's through the firm's preliminary results to June 2019.

The vaccines specialist posted an 8% boost to revenues on a constant currencies basis to £73.7mln, giving ‘pre-R&D’ operating earnings of £11.3mln, up 22%. 

European market share grew by half a percentage point to 14.1%.

Quick facts: Allergy Therapeutics PLC

Price: 11.25 GBX

AIM:AGY
Market: AIM
Market Cap: £71.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Allergy Therapeutics PLC named herein, including the promotion by the Company of Allergy Therapeutics PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Benchmark Holdings identifies breakthrough to help Tilapia fight disease

Top stories from the Proactive Investors UK newsroom. Aquaculture specialist Benchmark (LON:BMK) has claimed a breakthrough that might increase genetic resistance to a major infection in tilapia. The company has identified a strain of DNA that can help the fish fight off the disease more...

on 11/7/19

2 min read